JP6882172B2 - 神経変性疾患の治療に有用なｔｄｐ−４３結合性ポリペプチド - Google Patents

神経変性疾患の治療に有用なｔｄｐ−４３結合性ポリペプチド Download PDF

Info

Publication number
JP6882172B2
JP6882172B2 JP2017529766A JP2017529766A JP6882172B2 JP 6882172 B2 JP6882172 B2 JP 6882172B2 JP 2017529766 A JP2017529766 A JP 2017529766A JP 2017529766 A JP2017529766 A JP 2017529766A JP 6882172 B2 JP6882172 B2 JP 6882172B2
Authority
JP
Japan
Prior art keywords
antigen
tdp
seq
binding construct
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017529766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502561A (ja
JP2018502561A5 (https=
Inventor
ジャン−ピエール ジュリアン，
ジャン−ピエール ジュリアン，
クロード グラヴェル，
クロード グラヴェル，
シルヴィア ポッツィ，
シルヴィア ポッツィ，
Original Assignee
ユニバルシテ ラバル
ユニバルシテ ラバル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバルシテ ラバル, ユニバルシテ ラバル filed Critical ユニバルシテ ラバル
Publication of JP2018502561A publication Critical patent/JP2018502561A/ja
Publication of JP2018502561A5 publication Critical patent/JP2018502561A5/ja
Application granted granted Critical
Publication of JP6882172B2 publication Critical patent/JP6882172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
JP2017529766A 2014-12-05 2015-12-07 神経変性疾患の治療に有用なｔｄｐ−４３結合性ポリペプチド Active JP6882172B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462088012P 2014-12-05 2014-12-05
US62/088,012 2014-12-05
CA2,874,083 2014-12-05
CA2874083A CA2874083C (en) 2014-12-05 2014-12-05 Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
PCT/CA2015/051280 WO2016086320A1 (en) 2014-12-05 2015-12-07 Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2018502561A JP2018502561A (ja) 2018-02-01
JP2018502561A5 JP2018502561A5 (https=) 2019-01-24
JP6882172B2 true JP6882172B2 (ja) 2021-06-02

Family

ID=56090779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529766A Active JP6882172B2 (ja) 2014-12-05 2015-12-07 神経変性疾患の治療に有用なｔｄｐ−４３結合性ポリペプチド

Country Status (6)

Country Link
US (1) US10202443B2 (https=)
EP (1) EP3227330B1 (https=)
JP (1) JP6882172B2 (https=)
AU (2) AU2015358266A1 (https=)
CA (1) CA2874083C (https=)
WO (1) WO2016086320A1 (https=)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2352763T5 (pl) * 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
WO2014059442A2 (en) * 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
HRP20200384T1 (hr) * 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
EP3327038B1 (en) * 2013-12-20 2020-09-23 F. Hoffmann-La Roche AG Bispecific her2 antibodies and methods of use
RU2678810C2 (ru) * 2014-02-02 2019-02-01 Медиммун Лимитед ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα
KR20230104759A (ko) 2014-09-30 2023-07-10 뉴리뮨 홀딩 아게 인간-유래의 항-디펩티드 반복체(dpr) 항체
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
US11130815B2 (en) 2015-06-24 2021-09-28 Jcr Pharmaceuticals Co., Ltd. Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
TWI769982B (zh) * 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
KR102770650B1 (ko) 2015-07-06 2025-02-19 유씨비 바이오파마 에스알엘 타우 결합 항체
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
FI3334761T3 (fi) * 2015-08-13 2023-08-14 Univ New York Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
WO2017176835A2 (en) * 2016-04-06 2017-10-12 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
KR20190022632A (ko) 2016-06-20 2019-03-06 에프-스타 베타 리미티드 Lag-3 결합 구성원
CA3030754C (en) * 2016-07-20 2022-04-26 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
WO2018018031A1 (en) * 2016-07-22 2018-01-25 New York University Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides
CN117820467A (zh) * 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
MA48595A (fr) 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
RU2768404C2 (ru) * 2016-12-23 2022-03-24 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
AU2017385274B2 (en) 2016-12-26 2024-02-22 Jcr Pharmaceuticals Co., Ltd. Fusion protein including BDNF
TWI761413B (zh) 2016-12-26 2022-04-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
US12049493B2 (en) * 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
CN118184777A (zh) * 2017-01-30 2024-06-14 亚力兄制药公司 单价抗备解素抗体及抗体片段
EP3580241A4 (en) * 2017-02-10 2021-01-06 The Trustees Of The University Of Pennsylvania ANTIFACTOR D ANTIBODIES AND USES THEREOF
US11578137B2 (en) * 2017-03-06 2023-02-14 The Trustees Of The University Of Pennsylvania Anti-C5 antibodies and uses thereof
BR112019019595A2 (pt) * 2017-03-23 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
EP3601346A1 (en) * 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN110691793A (zh) * 2017-04-26 2020-01-14 田边三菱制药株式会社 黏结蛋白聚糖-1（cd138）结合剂及其用
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
CA3064785A1 (en) * 2017-05-30 2018-12-06 The University Of British Columbia Epitopes in the rna recognition motif 1 (rrm1) of tdp-43 and misfolding-selective antibodies thereto
EP3431496A1 (en) * 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
JP7204235B2 (ja) * 2017-08-02 2023-01-16 ストレスマーク・バイオサイエンシーズ・インコーポレイテッド 活性型α－シヌクレインに結合する抗体
JP7356727B2 (ja) * 2017-10-12 2023-10-05 慶應義塾 アクアポリン３（ａｑｐ３）の細胞外ドメインに特異的に結合する抗ａｑｐ３モノクローナル抗体、及びその使用
KR20200106495A (ko) * 2017-11-29 2020-09-14 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 암 치료요법을 위한 조성물 및 방법
AU2018379306A1 (en) * 2017-12-05 2020-06-25 Mabion Sa Combination therapy of multiple sclerosis comprising a CD20 ligand
WO2019118906A2 (en) * 2017-12-14 2019-06-20 University Of Florida Research Foundation Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
WO2019113711A1 (en) 2017-12-14 2019-06-20 University Of Ottawa Exosome packaging and targeted autophagy
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SURROGATES AND THEIR USES
CN111699003B (zh) * 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7490565B2 (ja) * 2017-12-29 2024-05-27 アレクトル エルエルシー 抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
EP3735422A1 (en) * 2018-01-05 2020-11-11 AC Immune SA Misfolded tdp-43 binding molecules
EP3746478A4 (en) * 2018-01-29 2022-01-19 The Regents of The University of California THERAPIES AND METHODS OF TREATING TLR2-MEDIATED DISEASES AND DISORDERS
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
CN112204050B (zh) 2018-01-31 2025-03-14 艾莱克特有限责任公司 抗ms4a6a抗体及其使用方法
JP7539834B2 (ja) * 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
WO2019161384A1 (en) * 2018-02-19 2019-08-22 New York University Tau single domain antibodies
KR20200130324A (ko) 2018-02-23 2020-11-18 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Cd83-결합 키메라 항원 수용체
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
TWI791794B (zh) * 2018-03-20 2023-02-11 瑞士商諾華公司 藥物組合
AU2018418224B2 (en) 2018-04-09 2025-04-17 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
BR112020020787A2 (pt) * 2018-04-11 2021-02-02 Tychan Pte. Ltd. métodos e composições para o tratamento de febre amarela
CN112004558A (zh) * 2018-04-12 2020-11-27 米迪亚制药有限责任公司 Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
CA3097999A1 (en) * 2018-04-24 2019-10-31 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
KR20210005096A (ko) * 2018-04-25 2021-01-13 메디뮨 리미티드 인간 항-pd-l1 항체의 제형
BR112020021855A2 (pt) 2018-04-27 2021-02-23 Biogen Ma Inc. anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
US11613571B2 (en) * 2018-05-23 2023-03-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
WO2019225787A1 (ko) * 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
WO2019229296A1 (en) * 2018-05-29 2019-12-05 Teknologian Tutkimuskeskus Vtt Oy Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment
EP3802600A1 (en) * 2018-05-31 2021-04-14 Ichnos Sciences S.A. Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
KR20210031694A (ko) * 2018-06-14 2021-03-22 베쓰 이스라엘 디코니스 메디칼 센터 인크 엑토뉴클레오티다제 억제 및 항체-매개된 표적 사이토시스를 통한 t-세포 고갈을 예방 또는 역전시키는 조성물 및 방법
JP7513533B2 (ja) * 2018-07-02 2024-07-09 アブセントラ，エルエルシー リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
PL3820569T3 (pl) 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
BR112021000282A2 (pt) * 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a cd137 e ox40
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
CN110713537B (zh) * 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
WO2020033646A1 (en) * 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
KR102666754B1 (ko) * 2018-08-21 2024-05-17 에이비엘바이오 주식회사 항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도
CA3111396A1 (en) 2018-09-06 2020-03-12 The Trustees Of The University Of Pennsylvania Humanized anti-c5 antibodies and uses thereof
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
US12269874B2 (en) * 2018-12-03 2025-04-08 mAbProtein Co., Ltd. Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
US20220040230A1 (en) * 2018-12-11 2022-02-10 The Regents Of The University Of California Compositions and methods for immunotherapies
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
AU2020221324A1 (en) * 2019-02-15 2021-09-02 University Of Southern California Lym-1 and Lym-2 antibody compositions and improved CAR constructs
EP3924389A4 (en) * 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
CN113661175A (zh) 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
WO2020206232A1 (en) * 2019-04-04 2020-10-08 Vanderbilt University Hiv/hcv cross-reactive antibodies and uses thereof
EP3958903A4 (en) * 2019-04-24 2023-08-02 Janssen Biotech, Inc. ANTIBODY FORMULATION
WO2020225736A1 (en) * 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
TW202110878A (zh) * 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
WO2020228806A1 (zh) * 2019-05-16 2020-11-19 齐鲁制药有限公司 针对密蛋白18a2的抗体及其应用
US20220235142A1 (en) * 2019-06-04 2022-07-28 Shanghai GenBase Biotechnology Co., Ltd. Anti-ceacam5 monoclonal antibody, preparation method thereof and use thereof
WO2020250204A1 (ko) * 2019-06-13 2020-12-17 프레스티지 바이오파마 피티이. 엘티디. 신규 cthrc1에 특이적 항체 및 이의 용도
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
MY205369A (en) * 2019-07-26 2024-10-17 Sinocelltech Ltd Humanized anti-il17a antibody and use thereof
MX2022001260A (es) * 2019-07-31 2022-04-18 Alector Llc Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
AU2020334893A1 (en) * 2019-08-16 2022-02-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Chimeric antigen receptors for treating myeloid malignancies
WO2021057930A1 (en) * 2019-09-26 2021-04-01 Wuxi Biologics (Shanghai) Co., Ltd. A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof
WO2021058718A1 (en) * 2019-09-26 2021-04-01 Roche Diagnostics Gmbh Anti-csf-1r antibody
EP4041757A4 (en) * 2019-09-26 2024-04-17 Regents of the University of Minnesota VIRAL ANTIGEN BINDING NK ENGAGERS COMPOUNDS AND METHODS OF USE
AU2020360849A1 (en) * 2019-09-30 2022-04-14 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Protein binders to iRhom2 epitopes
EP4041308A1 (en) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
AU2020380588A1 (en) * 2019-11-04 2022-06-09 Medimmune Limited Anti IL-33 therapeutic agent FPR treating renal disorders
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体
US20220275103A1 (en) * 2019-11-18 2022-09-01 CentricsBio, Inc. Anti-cd300c monoclonal antibody and biomarker thereof for preventing or treating cancer
WO2021102131A1 (en) * 2019-11-21 2021-05-27 Brown University Bispecific antibodies against chi3l1 and ctla4 with enhanced cytotoxic effects on tumor cells
WO2021110930A1 (en) * 2019-12-06 2021-06-10 Universiteit Antwerpen Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
MX2022007688A (es) * 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
WO2021146218A1 (en) * 2020-01-13 2021-07-22 Truebinding, Inc. Anti-gal3 antibodies and methods of use
JP7449390B2 (ja) * 2020-01-24 2024-03-13 ファイザー・インク 抗ｅ－セレクチン抗体、組成物および使用の方法
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021158178A1 (en) * 2020-02-07 2021-08-12 Agency For Science, Technology And Research Antigen-binding molecules against alppl2 and/or alpp and uses thereof
MX2022009476A (es) * 2020-02-10 2022-08-22 Regeneron Pharma Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
WO2021163346A2 (en) * 2020-02-12 2021-08-19 The Scripps Research Institute Long-acting gm-csf and methods of use
WO2021162394A1 (ko) * 2020-02-14 2021-08-19 충북대학교 산학협력단 B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
GB202003632D0 (en) * 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
US20230192877A1 (en) * 2020-03-30 2023-06-22 National Institutes Of Biomedical Inovation, Health And Nutriton Epitope region-bridging biparatopic antibody and method for producing same
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
BR112022021604A2 (pt) * 2020-04-28 2022-12-06 Sola Biosciences Llc Composições e métodos para tratamento de proteinopatias associadas à tdp-43
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
MX2022014734A (es) * 2020-05-26 2023-03-15 Regeneron Pharma Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
CN116323665A (zh) * 2020-05-29 2023-06-23 23和我公司 抗cd200r1抗体及其使用方法
KR20230020521A (ko) * 2020-06-04 2023-02-10 셀벡스 피티와이 리미티드 아고니스트 항-cd40 항체
US20230341408A1 (en) * 2020-06-08 2023-10-26 University Of Florida Research Foundation, Inc. Materials and methods for the diagnosis and treatment of cancer
CA3182384A1 (en) * 2020-06-18 2021-12-23 Jay M. Short Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR20230038706A (ko) * 2020-07-16 2023-03-21 난징 레전드 바이오테크 씨오., 엘티디. Cd19 결합 분자 및 이의 용도
US20230257475A1 (en) * 2020-07-16 2023-08-17 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric antigen receptors and uses thereof
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
EP4188960A4 (en) * 2020-08-03 2024-09-11 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION IN VIROTHERAPEUTIC PRODUCTS
WO2022034920A1 (en) * 2020-08-14 2022-02-17 Chugai Seiyaku Kabushiki Kaisha One-armed antigen-binding molecules and uses thereof
US12129290B2 (en) * 2020-08-18 2024-10-29 Omeros Corporation Monoclonal antibodies, compositions and methods for detecting complement factor D
EP4199968A1 (en) * 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
TWI818308B (zh) * 2020-09-03 2023-10-11 大陸商和鉑醫藥（上海）有限責任公司 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用
US12448449B2 (en) * 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
US11905332B2 (en) 2020-09-18 2024-02-20 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
KR20230088370A (ko) * 2020-09-18 2023-06-19 아이크노스 사이언스 에스. 아. Cd47-cd38 이중특이성 항체
WO2022068141A1 (zh) * 2020-09-29 2022-04-07 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
WO2022072508A1 (en) * 2020-09-30 2022-04-07 Dren Bio, Inc. Anti-cd94 antibodies and methods of use thereof
EP4236988A4 (en) * 2020-10-30 2024-10-30 Rush University Medical Center INTRANASAL IMMUNOTHERAPY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CN117264060A (zh) * 2020-11-09 2023-12-22 江苏中新医药有限公司 抗胞外-5’-核苷酸酶的抗体及其在制备肿瘤药物中的应用
CN114470189B (zh) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Ngf抗体在cipn性疼痛中的应用
JP7326584B2 (ja) * 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用
AR124410A1 (es) * 2020-12-18 2023-03-22 Ac Immune Sa Administración de anticuerpos
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
CN116635426A (zh) * 2021-01-08 2023-08-22 北京韩美药品有限公司 特异性结合cd47的抗体及其抗原结合片段
CA3204552A1 (en) * 2021-01-08 2022-07-14 Joseph M. LUETTGEN Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) * 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
MX2023010917A (es) * 2021-03-18 2023-09-27 Medimmune Ltd Molecula de union terapeutica que se une a ccr9.
TW202304988A (zh) * 2021-03-24 2023-02-01 美商健生生物科技公司 靶向ＣＤ７９ｂ、ＣＤ２０、及ＣＤ３之三特異性抗體
CN118165109A (zh) * 2021-03-31 2024-06-11 美勒斯公司 包含新颖pd-1结合域之多特异性结合部分
US11993654B2 (en) * 2021-03-31 2024-05-28 Merus N.V. PD-1 binding domains
PE20232050A1 (es) * 2021-04-06 2023-12-27 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段
WO2022271884A2 (en) * 2021-06-22 2022-12-29 Twist Bioscience Corporation Methods and compositions relating to covid antibody epitopes
TWI864408B (zh) * 2021-06-25 2024-12-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
AU2022299846B2 (en) * 2021-06-25 2024-08-15 Chugai Seiyaku Kabushiki Kaisha Anti–ctla-4 antibody
US12448451B2 (en) * 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
IL310012A (en) * 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
US11542340B1 (en) * 2021-10-29 2023-01-03 Biodesix, Inc. Antibodies targeting pulmonary nodule specific biomarkers and uses thereof
IL313265A (en) 2021-12-06 2024-08-01 Regeneron Pharma Antagonistic antibodies against NPR1 and methods of using them
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
CN120513256A (zh) * 2023-01-20 2025-08-19 迈威(美国)生物治疗有限公司 抗淀粉样蛋白β原纤丝/低聚物抗体和其用途
US20240285789A1 (en) * 2023-02-23 2024-08-29 University Of Utah Research Foundation Compositions and Methods for Killing PD-1 Positive Cells
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2025257181A1 (en) * 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
DK159088C (da) 1988-04-06 1991-01-28 Oce Helioprint As Skanner til aftastning af en original
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO1990001063A1 (en) 1988-07-23 1990-02-08 Delta Biotechnology Limited New secretory leader sequences
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US20040214167A9 (en) 2000-12-28 2004-10-28 Akio Matsuda NF-kappa B activating gene
MXPA05012722A (es) 2003-05-27 2006-05-25 Attenuon Llc Analogos de tiotungstato y sus usos.
WO2008042190A2 (en) 2006-09-29 2008-04-10 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
US8354236B2 (en) 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
US9557271B2 (en) 2008-09-25 2017-01-31 Mohammad A. Mazed Optical biomodule for detection of diseases
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2008151055A1 (en) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
WO2009008529A1 (ja) 2007-07-06 2009-01-15 Tokyo Metropolitan Organization For Medical Research Ｔｄｐ－４３凝集物に特異的に結合する抗体
GB0719287D0 (en) 2007-10-03 2007-11-14 Univ Manchester Prognostic or diagnostic test
CA2713871C (en) 2008-02-01 2018-05-22 Washington University In St. Louis Sequences associated with tdp-43 proteinopathies and methods of using the same
EP2272955B1 (en) 2008-04-09 2015-08-26 Tokyo Metropolitan Institute of Medical Science Tdp-43-storing cell model
KR20110013409A (ko) * 2008-05-23 2011-02-09 삼성전자주식회사 항체-펩티드 융합 상승체
WO2010015040A1 (en) 2008-08-07 2010-02-11 Powmri Ltd Therapy and prevention of tdp-43 proteinopathy
JP5756014B2 (ja) * 2008-08-08 2015-07-29 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） がんの診断および治療のためのｖｈｚ
US20110230551A1 (en) 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US20110287953A1 (en) 2010-05-21 2011-11-24 Chi-Ying Huang Method for discovering potential drugs
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
US8598339B2 (en) 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof
US20140120562A1 (en) 2011-06-22 2014-05-01 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease

Also Published As

Publication number Publication date
WO2016086320A1 (en) 2016-06-09
EP3227330A4 (en) 2018-10-31
JP2018502561A (ja) 2018-02-01
EP3227330A1 (en) 2017-10-11
EP3227330C0 (en) 2024-01-17
AU2021250947A1 (en) 2021-11-11
US20170355756A1 (en) 2017-12-14
CA2874083C (en) 2024-01-02
CA2874083A1 (en) 2016-06-05
AU2015358266A1 (en) 2017-06-29
EP3227330B1 (en) 2024-01-17
US10202443B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
JP6882172B2 (ja) 神経変性疾患の治療に有用なｔｄｐ−４３結合性ポリペプチド
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
US11814426B2 (en) Anti-tenascin C antibodies and uses thereof
CN110099924B (zh) Gremlin-1晶体结构和抑制性抗体
KR102811560B1 (ko) 동종형 선택적 항-tgf-베타 항체 및 이용 방법
US20220332804A1 (en) Complement C2 Binding Proteins and Uses Thereof
JP7668013B2 (ja) Ａｌｋ２／ａｃｖｒ１の細胞外領域を認識する抗体
CN107614524A (zh) 治疗
KR102953475B1 (ko) 항-EphA4 항체
EP4269588A1 (en) Anti-epha4 antibody
RU2786909C2 (ru) Связывающие белки и способы их применения
WO2026059969A1 (en) Human pd-1 and ctla4 neutralizing vhh antibodies and methods of use thereof
JP2026507922A (ja) 制御性ｔ細胞表面抗原のエピトープおよびこれに特異的に結合する抗体
WO2024076375A1 (en) Glypican 3 antibody and related methods
KR20220027825A (ko) 항-EphA4 항체
HK40010475A (en) Gremlin-1 crystal structure and inhibitory antibody
HK40010475B (zh) Gremlin-1晶体结构和抑制性抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181206

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210506

R150 Certificate of patent or registration of utility model

Ref document number: 6882172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250